SO-1 Prognostic nomogram to predict overall survival in patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: Real-world results from the multicenter retrospective study (NAPOLEON study)

T Shibuki,T Mizuta,M Shimokawa,F Koga,Y Ueda,J Nakazawa,A Komori,S Arima,M Fukahori,A Makiyama,H Taguchi,T Honda,K Mitsugi,K Nio,Y Ide,N Ureshino,T Shirakawa,T Otsuka

doi:10.1016/j.annonc.2020.04.016

SO-1 Prognostic nomogram to predict overall survival in patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: Real-world results from the multicenter retrospective study (NAPOLEON study)

T Shibuki, T Mizuta + Show 16 more

Open Access

https://doi.org/10.1016/j.annonc.2020.04.016

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Jul 1, 2020
License type: publisher-specific-oa

Affiliation: National Cancer Center Hospital East, Nishikawa Hospital, National Hospital Organization Kyushu Cancer Center, Saga-Ken Medical Centre Koseikan, Japanese Red Cross Kumamoto Hospital, Kagoshima City Hospital, Oita University, Kagoshima University, Kurume University, Japan Community Healthcare Organization, Kyushu Hospital, Sendai Shakai Hoken Hospital, Nagasaki University, Sasebo City General Hospital, Takamatsu Red Cross Hospital, Japan Medical Association

#Gemcitabine Plus Nab-paclitaxel #American Joint Committee On Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Although the American Joint Committee on Cancer (AJCC) TNM classification is used as a traditional staging system for cancer, the survival of patients with unresectable pancreatic cancer (uPC) varies even in patients with the same AJCC stage. A nomogram has been recognized as a reliable alternative tool to predict prognosis in different cancer settings; however, the one for patients with uPC treated with gemcitabine plus nab-paclitaxel (GnP) or FOLFIRINOX, which was considered as the standard treatments in uPC, has not been fully debated.

Full Text